APA (7th ed.) Citation

T, P., M, V., JM, C., E, V., E, S., G, V., . . . A, P. (2026). Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: A window-of-opportunity phase II trial (SOLTI-1503 PROMETEO). Nature communications, 17(1), . https://doi.org/10.1038/s41467-026-69222-5

Chicago Style (17th ed.) Citation

T, Pascual, et al. "Talimogene Laherparepvec and Atezolizumab in HER2-negative Breast Cancer Following Neoadjuvant Chemotherapy: A Window-of-opportunity Phase II Trial (SOLTI-1503 PROMETEO)." Nature Communications 17, no. 1 (2026). https://doi.org/10.1038/s41467-026-69222-5.

MLA (9th ed.) Citation

T, Pascual, et al. "Talimogene Laherparepvec and Atezolizumab in HER2-negative Breast Cancer Following Neoadjuvant Chemotherapy: A Window-of-opportunity Phase II Trial (SOLTI-1503 PROMETEO)." Nature Communications, vol. 17, no. 1, 2026, https://doi.org/10.1038/s41467-026-69222-5.